{"id":"NCT02766608","sponsor":"Pearl Therapeutics, Inc.","briefTitle":"Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD","officialTitle":"A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05-31","primaryCompletion":"2017-12-01","completion":"2017-12-01","firstPosted":"2016-05-10","resultsPosted":"2019-09-24","lastUpdate":"2019-09-24"},"enrollment":2389,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disorder"],"interventions":[{"type":"DRUG","name":"BFF MDI 320/9.6 μg","otherNames":["Budesonide and Formoterol Fumarate Inhalation Aerosol"]},{"type":"DRUG","name":"BFF MDI 160/9.6 μg","otherNames":["Budesonide and Formoterol Fumarate Inhalation Aerosol"]},{"type":"DRUG","name":"FF MDI 9.6 μg","otherNames":["Formoterol Fumarate Inhalation Aerosol"]},{"type":"DRUG","name":"BD MDI 320 μg","otherNames":["Budesonide Inhalation Aerosol"]},{"type":"DRUG","name":"Symbicort® TBH 400/12 μg BID","otherNames":["Symbicort® Turbuhaler"]}],"arms":[{"label":"BFF MDI 320/9.6 μg","type":"EXPERIMENTAL"},{"label":"BFF MDI 160/9.6 μg","type":"EXPERIMENTAL"},{"label":"FF MDI 9.6 μg","type":"EXPERIMENTAL"},{"label":"BD MDI 320 μg","type":"EXPERIMENTAL"},{"label":"Symbicort® TBH 400/12 μg","type":"OTHER"}],"summary":"This is a Phase III randomized, double-blind, parallel group, multi-center, 24-week lung function study with BFF MDI (320/9.6 μg and 160/9.6 μg) compared to FF MDI 9.6 μg, BD MDI 320 μg, and open-label Symbicort® TBH (200/6 μg) administered BID.","primaryOutcome":{"measure":"Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI Versus FF MDI)","timeFrame":"at Week 24","effectByArm":[{"arm":"BFF MDI 320/9.6 μg","deltaMin":0.036,"sd":null},{"arm":"BFF MDI 160/9.6 μg","deltaMin":0.017,"sd":null},{"arm":"FF MDI 9.6 μg","deltaMin":-0.003,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":259,"countries":["United States","Canada","Czechia","Germany","Hungary","Poland","Russia","South Korea"]},"refs":{"pmids":["35815359","30220648"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4181&filename=PT009002_TELOS_PROTOCOL_REDACTED_07AUG2018_PDFA.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4181&filename=d7820c00001-12-1-09-Final_sap_PDFA.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4181&filename=PT009002_TELOS_PROTOCOL_REDACTED_PDFA.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4181&filename=PT009002_Final_sap_Redacted_PDFA.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":42,"n":655},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Chronic obstructive pulmonary disease","Hypertension","Back pain"]}}